Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection

Francis J Zamora,1,2 Ellen Dowers,2 Faiza Yasin,3 Onyema Ogbuagu3 1Department of Pharmacy Services, Broward Health Medical Center, Fort Lauderdale, FL, USA; 2Department of Pharmacy Services, Yale-New Haven Hospital, New Haven, CT, USA; 3Section of Infectious Diseases, Yale AIDS Program, Yale Univers...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zamora FJ, Dowers E, Yasin F, Ogbuagu O
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	dolutegravir lamivudine combination antiretroviral therapy Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/134e70daf0d848d3b33efb2378bc5b49
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:134e70daf0d848d3b33efb2378bc5b49
record_format	dspace
spelling	oai:doaj.org-article:134e70daf0d848d3b33efb2378bc5b492021-12-02T03:21:56ZDolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection1179-1373https://doaj.org/article/134e70daf0d848d3b33efb2378bc5b492019-10-01T00:00:00Zhttps://www.dovepress.com/dolutegravir-and-lamivudine-combination-for-the-treatment-of-hiv-1-inf-peer-reviewed-article-HIVhttps://doaj.org/toc/1179-1373Francis J Zamora,1,2 Ellen Dowers,2 Faiza Yasin,3 Onyema Ogbuagu3 1Department of Pharmacy Services, Broward Health Medical Center, Fort Lauderdale, FL, USA; 2Department of Pharmacy Services, Yale-New Haven Hospital, New Haven, CT, USA; 3Section of Infectious Diseases, Yale AIDS Program, Yale University School of Medicine, New Haven, CT, USACorrespondence: Onyema OgbuaguSection of Infectious Diseases, Yale AIDS Program, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT 06510, USATel +1 516-281-4557Fax 1 203 737 4051Email onyema.ogbuagu@yale.eduAbstract: There have been remarkable advances in drug development for the treatment of HIV-1 infection. From the co-formulation of combination antiretroviral therapy (cART) into single-tablet regimens to the development of long-acting antiretroviral (ARV) drug formulations, the treatment of HIV has and will become much more tolerable and less complicated for patients. In addition, and appropriately, there is a focus on reducing short- and long-term toxicities of treatment while maintaining robust efficacy. One of such approaches includes 2-drug regimen constructs that contain and retain effective ARV compounds while excluding components that have relatively unfavorable toxicity profiles. The first-ever 2-drug regimen approved for the treatment of HIV-1 infection for treatment-naive people living with HIV (PLWH), consisting of the integrase inhibitor dolutegravir (DTG) and the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine (3TC), is reviewed in this paper. The chemical composition and properties, pharmacokinetic and pharmacodynamics profile, and clinical trial data on efficacy and safety of DTG/3TC are presented. An expert opinion aims to highlight important considerations for the use of DTG/3TC in the context of existing and emerging ARV options.Keywords: dolutegravir, lamivudine, combination antiretroviral therapyZamora FJDowers EYasin FOgbuagu ODove Medical Pressarticledolutegravirlamivudinecombination antiretroviral therapyImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol Volume 11, Pp 255-263 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	dolutegravir lamivudine combination antiretroviral therapy Immunologic diseases. Allergy RC581-607
spellingShingle	dolutegravir lamivudine combination antiretroviral therapy Immunologic diseases. Allergy RC581-607 Zamora FJ Dowers E Yasin F Ogbuagu O Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
description	Francis J Zamora,1,2 Ellen Dowers,2 Faiza Yasin,3 Onyema Ogbuagu3 1Department of Pharmacy Services, Broward Health Medical Center, Fort Lauderdale, FL, USA; 2Department of Pharmacy Services, Yale-New Haven Hospital, New Haven, CT, USA; 3Section of Infectious Diseases, Yale AIDS Program, Yale University School of Medicine, New Haven, CT, USACorrespondence: Onyema OgbuaguSection of Infectious Diseases, Yale AIDS Program, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT 06510, USATel +1 516-281-4557Fax 1 203 737 4051Email onyema.ogbuagu@yale.eduAbstract: There have been remarkable advances in drug development for the treatment of HIV-1 infection. From the co-formulation of combination antiretroviral therapy (cART) into single-tablet regimens to the development of long-acting antiretroviral (ARV) drug formulations, the treatment of HIV has and will become much more tolerable and less complicated for patients. In addition, and appropriately, there is a focus on reducing short- and long-term toxicities of treatment while maintaining robust efficacy. One of such approaches includes 2-drug regimen constructs that contain and retain effective ARV compounds while excluding components that have relatively unfavorable toxicity profiles. The first-ever 2-drug regimen approved for the treatment of HIV-1 infection for treatment-naive people living with HIV (PLWH), consisting of the integrase inhibitor dolutegravir (DTG) and the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine (3TC), is reviewed in this paper. The chemical composition and properties, pharmacokinetic and pharmacodynamics profile, and clinical trial data on efficacy and safety of DTG/3TC are presented. An expert opinion aims to highlight important considerations for the use of DTG/3TC in the context of existing and emerging ARV options.Keywords: dolutegravir, lamivudine, combination antiretroviral therapy
format	article
author	Zamora FJ Dowers E Yasin F Ogbuagu O
author_facet	Zamora FJ Dowers E Yasin F Ogbuagu O
author_sort	Zamora FJ
title	Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
title_short	Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
title_full	Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
title_fullStr	Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
title_full_unstemmed	Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
title_sort	dolutegravir and lamivudine combination for the treatment of hiv-1 infection
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/134e70daf0d848d3b33efb2378bc5b49
work_keys_str_mv	AT zamorafj dolutegravirandlamivudinecombinationforthetreatmentofhiv1infection AT dowerse dolutegravirandlamivudinecombinationforthetreatmentofhiv1infection AT yasinf dolutegravirandlamivudinecombinationforthetreatmentofhiv1infection AT ogbuaguo dolutegravirandlamivudinecombinationforthetreatmentofhiv1infection
_version_	1718401776741253120

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection

Ejemplares similares